Ongoing Trials May Pave Way To Bring Later-Line Therapies Upfront in Newly Diagnosed Multiple Myeloma
Ravi Vij, MD, MBA, suggested that 4-drug regimens may be a new standard for frontline therapy in newly diagnosed multiple myeloma, as oncologists await trial readouts from ongoing clinical trials.
EP: 1.SWOG S0777 Trial Proves VRd To Be Viable Option for Untreated Myeloma That Is Unintended for ASCT
EP: 2.Expert Offers Considerations For Frontline Combination Therapies in Multiple Myeloma
EP: 3.Ongoing Trials May Pave Way To Bring Later-Line Therapies Upfront in Newly Diagnosed Multiple Myeloma
EP: 4.MAIA trial Supports Use of D-Rd in Transplant-Ineligible Patients With Myeloma
EP: 5.GRIFFIN Trial Supports Use of Dara-VRd in Transplant-Eligble Patients With Myeloma
EP: 6.Ongoing Trials Aim to Determine Best Regimen for Transplant-Ineligible Patients With Myeloma
EP: 7.Future of Myeloma Treatment ‘Quite Exciting’ With New Immunotherapies
EP: 8.Recap: Alabama and Washington Universities Face-Off on Multiple Myeloma at ASH
As part of CancerNetwork’s Face-Off video series, Ravi Vij, MD, MBA, professor, Department of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia at Washington University School of Medicine in St. Louis, discussed future directions and studies being done in the myeloma space.
Vij: I think that currently there are several ongoing clinical trials, the results of which are eagerly awaited, that are looking at actually bringing 4-drug regimens even for patients not headed to stem cell transplantation. The 4-drug regimens have become a mainstay of treatment for transplant eligible patients already. But for transplant ineligible patients, we still tend to use the 3-drug regimens.
So in the future adding a CD38 antibody, be it daratumumab (Darzalex) or isatuximab [Sarclisa] is expected to also become the standard of care once those trials looking at [2-, 3-, or 4-drug regimens] are presented at future meetings.
For patients with multiple myeloma, we are fortunate that we have made tremendous progress in the last 20 years with the mainstay of therapy being proteasome inhibitors, immunomodulatory drugs, and CD38 antibodies. We're entering a new era now with a whole new group of targets that have already shown their efficacy in later lines of therapy, including bi-specifics; CAR Ts to BCMA; and other targets including GPRC5D and FCRF5; data with cell mods; venetoclax [Venclexta] and 1114 translocation patients.
We expect that with time, these will move into the paradigm of treatment earlier in the course and will benefit even more patients with multiple myeloma.
Transcription edited for clarity.
